No abstract

Microgravity eases several constraints limiting experiments with ultracold and condensed atoms on ground. It enables extended times of flight without suspension and eliminates the gravitational sag for trapped atoms. These advantages motivated numerous initiatives to adapt and operate experimental setups on microgravity platforms. We describe the design of the payload, motivations for design choices, and capabilities of the Bose-Einstein Condensate and Cold Atom Laboratory (BECCAL), a NASA-DLR collaboration. BECCAL builds on the heritage of previous devices operated in microgravity, features rubidium and potassium, multiple options for magnetic and optical trapping, different methods for coherent manipulation, and will offer new perspectives for experiments on quantum optics, atom optics, and atom interferometry in the unique microgravity environment on board the International Space Station.

No abstract

BackgroundSince 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology and of Lipidologists and completed the data set for the registry according to the current guidelines and the German indication guideline for apheresis in 2009. In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 5 years now.Methods and resultsDuring the time period 2012–2016, 71 German apheresis centers collected retrospective and prospective observational data of 1435 patients undergoing lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from cardiovascular disease (CVD) or progressive CVD. A total of 15,527 completely documented LA treatments were entered into the database. All patients treated by LA showed a median LDL-C reduction rate of 67.5%, and a median Lp (a) reduction rate of 71.1%. Analog to the Pro(a)LiFe pattern, patient data were analyzed to the incidence rate of coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y‑1) and prospectively two years on LA treatment (y + 1 and y + 2). During two years of LA treatment a MACE reduction of 78% was observed. In the years considered, side effects of LA treatment were low (5.9%) and mainly comprised puncture problems.ConclusionsThe data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp (a) levels, progressive CVD, and maximally tolerated lipid lowering medication. In addition, LA treatments were found to be safe with a low rate of side effects.

No abstract